NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free ALLR Stock Alerts $0.45 -0.01 (-2.15%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.44▼$0.4850-Day Range$0.45▼$4.3052-Week Range$0.44▼$269.80Volume2.62 million shsAverage Volume3.14 million shsMarket Capitalization$1.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Allarity Therapeutics alerts: Email Address Allarity Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish6.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.60) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.07 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Allarity Therapeutics.Read more about Allarity Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.74% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently increased by 149.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLR. Previous Next 2.6 News and Social Media Coverage News SentimentAllarity Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Allarity Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for ALLR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.08% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.53% of the stock of Allarity Therapeutics is held by institutions.Read more about Allarity Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allarity Therapeutics are expected to grow in the coming year, from ($2.60) to ($1.56) per share.Read more about Allarity Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. About Allarity Therapeutics Stock (NASDAQ:ALLR)Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More ALLR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLR Stock News HeadlinesJune 13 at 5:18 AM | americanbankingnews.comAllarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 149.6% in MayMay 20, 2024 | globenewswire.comAllarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementMay 15, 2024 | investorplace.comALLR Stock Earnings: Allarity Therapeutics Reported Results for Q1 2024May 14, 2024 | globenewswire.comAllarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesMay 7, 2024 | globenewswire.comAllarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockMay 6, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 6, 2024 | finance.yahoo.comAllarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 6, 2024 | globenewswire.comAllarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 2, 2024 | msn.comWhy Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?May 2, 2024 | benzinga.comNasdaq Jumps Over 100 Points; Kellanova Posts Upbeat ResultsMay 2, 2024 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 39% Today?May 2, 2024 | finance.yahoo.comAllarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerMay 2, 2024 | globenewswire.comAllarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerApril 29, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementApril 29, 2024 | globenewswire.comAllarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementApril 17, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)April 17, 2024 | finance.yahoo.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 17, 2024 | globenewswire.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 12, 2024 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 41% Today?April 4, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitApril 4, 2024 | msn.comAllarity Therapeutics to implement 1-for-20 reverse stock splitApril 4, 2024 | globenewswire.comAllarity Therapeutics Announces 1-for-20 Reverse Stock SplitMarch 27, 2024 | globenewswire.comAllarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerMarch 25, 2024 | globenewswire.comAllarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)March 8, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateSee More Headlines Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLR CUSIPN/A CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,900,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-96.94% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($18.62) per share Price / Book-0.02Miscellaneous Outstanding Shares2,390,000Free Float2,384,000Market Cap$1.09 million OptionableNot Optionable Beta0.41 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Thomas H. Jensen (Age 46)Founder, CEO, Senior VP of Investor Relations & Director Ms. Joan Y. Brown (Age 70)Chief Financial Officer Comp: $180kMr. Peter Buhl Jensen Adj Professor (Age 69)M.D., M.D., Ph.D., Ph.D., Co-Founder Comp: $546.08kDr. Steen Meier Knudsen Ph.D. (Age 63)Founder & Chief Scientific Officer Comp: $185.11kKey CompetitorsArtelo BiosciencesNASDAQ:ARTLGT BiopharmaNASDAQ:GTBPVirios TherapeuticsNASDAQ:VIRICingulateNASDAQ:CINGKazia TherapeuticsNASDAQ:KZIAView All Competitors ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed in 2024? Allarity Therapeutics' stock was trading at $11.0220 at the beginning of 2024. Since then, ALLR stock has decreased by 95.9% and is now trading at $0.4549. View the best growth stocks for 2024 here. Are investors shorting Allarity Therapeutics? Allarity Therapeutics saw a increase in short interest in May. As of May 31st, there was short interest totaling 1,170,000 shares, an increase of 149.6% from the May 15th total of 468,800 shares. Based on an average daily volume of 3,990,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 6.7% of the company's shares are short sold. View Allarity Therapeutics' Short Interest. When is Allarity Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ALLR earnings forecast. How were Allarity Therapeutics' earnings last quarter? Allarity Therapeutics, Inc. (NASDAQ:ALLR) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($22.14) EPS for the quarter. When did Allarity Therapeutics' stock split? Allarity Therapeutics's stock reverse split on the morning of Tuesday, April 9th 2024. The 1-20 reverse split was announced on Tuesday, April 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLR) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.